Omigapil maleate (CGP3466B maleate) is a GAPDH nitrosylation inhibitor with oral activity, showing potential for the study of Alzheimer's disease by ameliorating Aβ1-42-induced tau acetylation, memory deficits, and motor dysfunction in mice; it is also a potent apoptosis inhibitor and can be used in the study of congenital muscular dystrophy (CMD); in vivo studies demonstrate that omigapil (0.1 mg/kg) improves muscle regeneration, increases muscle force, reduces muscle fiber loss, and significantly enhances multiple functional parameters in dyW/mag mice.